Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community

ARDX 10.22.2024

Full Press ReleaseSEC FilingsOur ARDX Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
  • 01.06.2025 - Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.16.2025 - 144 Report of proposed sale of securities
  • 01.13.2025 - 8-K Current report

WALTHAM, Mass.,Oct. 22, 2024(GLOBE NEWSWIRE) --Ardelyx, Inc.(Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch ofGut Matters: Discoveries and Innovations, a new podcast for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is hosted by Ardelyx’s director, patient advocacy,Johannah Ruddy,M.Ed. and practicing gastroenterologist,Andrea Shin, MD. The first episode is out now. Each month, the hosts will be joined by patients, caregivers, advocacy leaders, healthcare providers and other gastroenterology experts to discuss the impact of IBS-C and provide education and hope for those affected.

“People living with IBS-C often feel lonely and stigmatized. We wanted to create a safe space where people with this condition can find fact-based information, hear stories that likely sound like their own, and gain valuable insights that will provide them with hope as well as the tools to better manage their condition,” saidAndrea Shin, MD and podcast co-host. “I am really proud to be a part of theGut Matters: Discoveries and Innovationspodcast. Our hope is to empower patients, family members and caregivers by showing them that they are part of a large community.”

Individuals can subscribe to the podcast and keep up on the latest episodeshere, or wherever they get their podcasts.

About Irritable Bowel Syndrome with Constipation (IBS-C)Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 12 million people in theU.S.IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.

AboutArdelyxArdelyxwas founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs.Ardelyxhas two commercial products approved inthe United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor).Ardelyxhas agreements for the development and commercialization of tenapanor outside of theU.S.Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia inJapan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted inChinawith Fosun Pharma. Knight Therapeutics commercializes IBSRELA inCanada. For more information, please visithttps://ardelyx.com/and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:Caitlin Lowieclowie@ardelyx.com

Primary Logo

Source: Ardelyx, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com